In addition, CAPS in combination with cisplatin suppresses transforming growth factor-β1-induced epithelial–mesenchymal transition (EMT) through the activation of claudin 1 and inhibition of the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the tongue [95]. This evidence concerns the gene MTOR and tongue squamous cell carcinoma.